Cargando…
Poly(ADP-ribose) Polyremase-1 (PARP-1) Inhibition: A Promising Therapeutic Strategy for ETS-Expressing Tumours
ETS transcription factors are a highly conserved family of proteins involved in the progression of many cancers, such as breast and prostate carcinomas, Ewing’s sarcoma, and leukaemias. This significant involvement can be explained by their roles at all stages of carcinogenesis progression. Generall...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10487777/ https://www.ncbi.nlm.nih.gov/pubmed/37686260 http://dx.doi.org/10.3390/ijms241713454 |
_version_ | 1785103321476890624 |
---|---|
author | Legrand, Arnaud J. Choul-li, Souhaila Villeret, Vincent Aumercier, Marc |
author_facet | Legrand, Arnaud J. Choul-li, Souhaila Villeret, Vincent Aumercier, Marc |
author_sort | Legrand, Arnaud J. |
collection | PubMed |
description | ETS transcription factors are a highly conserved family of proteins involved in the progression of many cancers, such as breast and prostate carcinomas, Ewing’s sarcoma, and leukaemias. This significant involvement can be explained by their roles at all stages of carcinogenesis progression. Generally, their expression in tumours is associated with a poor prognosis and an aggressive phenotype. Until now, no efficient therapeutic strategy had emerged to specifically target ETS-expressing tumours. Nevertheless, there is evidence that pharmacological inhibition of poly(ADP-ribose) polymerase-1 (PARP-1), a key DNA repair enzyme, specifically sensitises ETS-expressing cancer cells to DNA damage and limits tumour progression by leading some of the cancer cells to death. These effects result from a strong interplay between ETS transcription factors and the PARP-1 enzyme. This review summarises the existing knowledge of this molecular interaction and discusses the promising therapeutic applications. |
format | Online Article Text |
id | pubmed-10487777 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-104877772023-09-09 Poly(ADP-ribose) Polyremase-1 (PARP-1) Inhibition: A Promising Therapeutic Strategy for ETS-Expressing Tumours Legrand, Arnaud J. Choul-li, Souhaila Villeret, Vincent Aumercier, Marc Int J Mol Sci Review ETS transcription factors are a highly conserved family of proteins involved in the progression of many cancers, such as breast and prostate carcinomas, Ewing’s sarcoma, and leukaemias. This significant involvement can be explained by their roles at all stages of carcinogenesis progression. Generally, their expression in tumours is associated with a poor prognosis and an aggressive phenotype. Until now, no efficient therapeutic strategy had emerged to specifically target ETS-expressing tumours. Nevertheless, there is evidence that pharmacological inhibition of poly(ADP-ribose) polymerase-1 (PARP-1), a key DNA repair enzyme, specifically sensitises ETS-expressing cancer cells to DNA damage and limits tumour progression by leading some of the cancer cells to death. These effects result from a strong interplay between ETS transcription factors and the PARP-1 enzyme. This review summarises the existing knowledge of this molecular interaction and discusses the promising therapeutic applications. MDPI 2023-08-30 /pmc/articles/PMC10487777/ /pubmed/37686260 http://dx.doi.org/10.3390/ijms241713454 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Legrand, Arnaud J. Choul-li, Souhaila Villeret, Vincent Aumercier, Marc Poly(ADP-ribose) Polyremase-1 (PARP-1) Inhibition: A Promising Therapeutic Strategy for ETS-Expressing Tumours |
title | Poly(ADP-ribose) Polyremase-1 (PARP-1) Inhibition: A Promising Therapeutic Strategy for ETS-Expressing Tumours |
title_full | Poly(ADP-ribose) Polyremase-1 (PARP-1) Inhibition: A Promising Therapeutic Strategy for ETS-Expressing Tumours |
title_fullStr | Poly(ADP-ribose) Polyremase-1 (PARP-1) Inhibition: A Promising Therapeutic Strategy for ETS-Expressing Tumours |
title_full_unstemmed | Poly(ADP-ribose) Polyremase-1 (PARP-1) Inhibition: A Promising Therapeutic Strategy for ETS-Expressing Tumours |
title_short | Poly(ADP-ribose) Polyremase-1 (PARP-1) Inhibition: A Promising Therapeutic Strategy for ETS-Expressing Tumours |
title_sort | poly(adp-ribose) polyremase-1 (parp-1) inhibition: a promising therapeutic strategy for ets-expressing tumours |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10487777/ https://www.ncbi.nlm.nih.gov/pubmed/37686260 http://dx.doi.org/10.3390/ijms241713454 |
work_keys_str_mv | AT legrandarnaudj polyadpribosepolyremase1parp1inhibitionapromisingtherapeuticstrategyforetsexpressingtumours AT choullisouhaila polyadpribosepolyremase1parp1inhibitionapromisingtherapeuticstrategyforetsexpressingtumours AT villeretvincent polyadpribosepolyremase1parp1inhibitionapromisingtherapeuticstrategyforetsexpressingtumours AT aumerciermarc polyadpribosepolyremase1parp1inhibitionapromisingtherapeuticstrategyforetsexpressingtumours |